# Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

Study · id `cardio:ct-nct07030621` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07030621](<https://clinicaltrials.gov/study/NCT07030621>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07030621

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 436 participants.

## Technical summary

Registry record NCT07030621. Randomized; double masking; primary purpose treatment. Start 2025-07-01 (anticipated); primary completion 2027-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 436 participants (planned count; ClinicalTrials.gov record NCT07030621, source copy `cardio:ctgov-nct07030621-2025-06-22`, retrieved 2026-10-26)
- Planned start: 2025-07-01 (anticipated) (ClinicalTrials.gov record NCT07030621, source copy `cardio:ctgov-nct07030621-2025-06-22`, retrieved 2026-10-26)
- Primary completion: 2027-07-31 (anticipated) (ClinicalTrials.gov record NCT07030621, source copy `cardio:ctgov-nct07030621-2025-06-22`, retrieved 2026-10-26)
- Completion: 2028-01-31 (anticipated) (ClinicalTrials.gov record NCT07030621, source copy `cardio:ctgov-nct07030621-2025-06-22`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07030621, source copy `cardio:ctgov-nct07030621-2025-06-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07030621-2025-06-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
- Acronym: STARS
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Semaglutide 0.5 mg
- Intervention (Drug): Normal Saline
- Lead sponsor: RenJi Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: RenJi Hospital (`cardio:org-renji-hospital`)

## Provenance

Content hash: b73f1855e192bd512b41deb491ac9b102057974267b692ffc3355b61fdf72516
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
